The Science Behind MCO
TECHNOLOGY DESIGNED TO CHANGE LIVES
The Science Behind MCO
TECHNOLOGY DESIGNED TO CHANGE LIVES
Nanoscope has developed the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration. Our MCO optogenetic platform is designed to revolutionize retinal disease management.
First investigational gene-agnostic therapy that is registration-ready for Retinitis Pigmentosa (RP) and Phase 3-ready for Stargardt disease
Only investigational therapy shown in a randomized, controlled clinical trial to restore durable broadband vision with ambient light sensitivity in patients with RP
Delivered as a one-time, in-office, intravitreal injection
Nanoscope has taken a fundamentally different approach to optogenetics, and is revolutionizing the treatment of retinal diseases through a natural light activatable platform that is designed to enable therapeutic targeting regardless of the underlying gene mutation.
WHAT ARE OPSINS AND HOW DO THEY WORK?
Optogenetics is a therapeutic approach that uses light to turn specific cells on or off. It offers great promise in the treatment of retinal diseases through therapies that “functionalize” retinal cells to become sensitive to light.
Nanoscope’s optogenetic technology is designed to make highly dense bipolar retinal cells light sensitive, preserving the visual processing circuitry by bypassing or supplementing dead photoreceptors.
There are over 100 known genes and 1,000 corresponding mutations that contribute to RP.
Nanoscope’s gene-agnostic optogenetic therapy has the potential to treat all of them without genetic testing.
MCO-010 is being developed for delivery by a one-time, in-office, intravitreal injection and is intended to provide durable restoration of vision while fitting into existing retinal specialist workflows with no genetic testing required to determine patient eligibility.
ADVANTAGES OF NANOSCOPE'S OPTOGENETIC THERAPY
- Single, one-time injection delivered in an office setting -- no hospitalization or surgery
- Does not require high-intensity stimulation or an external device
- Sensitive to all visible light and low light levels
- Fast response time after treatment
- Durable treatment effect over time
SCIENTIFIC PUBLICATIONS
Byron L. Lam, Vitaliy Zak, Victor H. Gonzalez, Ninel Z. Gregori, Sai H. Chavala, Subrata Batabyal, Michael Carlson, Sanghoon Kim, Ananta Ayyagari, Jean Chang, Hayley Lane, Nozhat Choudry, John Koester, Mark Von Tress, Jody Piltz-Seymour, Najam A. Sharif, Stephen H. Tsang, Vinit B. Mahajan, David S. Boyer, Allen C. Ho, Samarendra K. Mohanty
Samarendra Mohanty, Pratyajit Mohapatra, Amir Singh, William Marks, Subrata Batabyal, Michael Carlson, Najam Sharif, Sanghoon Kim
Samarendra K. Mohanty, Santosh Mahapatra, Subrata Batabyal, Michael Carlson, Gayatri Kanungo, Ananta Ayyagari, Kissaou Tchedre, Joel A. Franco, Michael Singer, Samuel B. Barone, Sai Chavala, Vinit B. Mahajan